Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, ...

The future of book adaptations is looking bright — and, well, a little terrifying. Hollywood is hungry for speculative epics imagining alternate realities grim enough to shake your faith in humanity.

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...

Blake Crouch's new novel, Recursion, is a thriller with a dash of sci-fi. It makes the case that we are the sum of our memories and asks what happens when our memories fail us. The novelist Blake ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Recursion Pharmaceuticals, Inc. ( RXRX) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST All right. Good morning, again, for I see some familiar face in the last one, but thanks ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...